Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed by a doctor with certain subtypes of peripheral T-cell lymphoma (PTCL), a type of blood cancer, as defined by a standard medical classification system — but not the skin-based or blood-based forms of these cancers.
• People who have at least one area of the disease that can be measured on a scan at the start of the trial.
• People whose cancer has come back or stopped responding to at least one previous treatment, such as chemotherapy, targeted therapy, immunotherapy, or a stem cell transplant using their own cells.
• People aged between 20 and 75 years old (inclusive).
• People who are generally well enough to carry out light activity and care for themselves, based on a standard medical fitness scale (ECOG score of 0 or 1).
• People who are expected to live for at least 12 weeks.
• People who have not had radiotherapy, chemotherapy, immunotherapy (other than antibody-based therapy), or targeted therapy in the 4 weeks before starting the trial drug.
• People who have not received any antibody-based therapy in the 12 weeks before starting the trial drug.
• People who are willing to sign a written consent form agreeing to take part.

Who may not be able to join:

• Women who are pregnant or breastfeeding, or women who could become pregnant and are not willing to use adequate contraception during the trial.
• People found to have lymphoma affecting the brain or spinal cord during the screening process.
• People who have previously been treated with a type of drug called an HDAC inhibitor.
• People with a history of certain serious heart conditions, including significant heart rhythm problems, a heart attack within the past year, heart failure, or other active heart disease requiring treatment.
• People who have excess fluid around the heart, as detected by an ultrasound scan, measuring 10 mm or more.
• People who have had an organ transplant in the past.
• People who have had a stem cell transplant using donor cells (allogeneic transplant).
• People who have had a stem cell transplant using their own cells within the 12 weeks before starting the trial drug.
• People who have taken part in another clinical trial involving an antibody therapy within the past 12 weeks, or any other investigational (experimental) therapy within the past 4 weeks.
• People who have received treatment to manage low blood cell counts caused by earlier treatment, within 7 days before starting the trial drug.
• People who have active bleeding, a newly diagnosed blood clot condition, or who are taking blood-thinning medication and have a tendency to bleed.
• People with an active hepatitis B or C infection, or who have had a persistent fever in the 14 days before starting the trial drug.
• People who have tested positive for HIV or have been diagnosed with AIDS.
• People who have had major surgery on an important organ within 6 weeks before starting the trial drug.
• People with abnormal liver function, kidney function, or blood counts that fall outside the levels specified by the trial (confirm with trial site for exact values).
• People with known serious mental health conditions or substance use disorders that could affect their ability to take part in or complete the trial.
• People whom the trial doctor considers unsuitable to participate for any other reason.

Important: Always verify eligibility with the trial site directly before applying.